Clinical Policy: Alopecia Areata Treatments
Customize your policy alerts
Sign up for mhn Policy HNCA.CP.CPA.04 alerts
Get alerted when Policy HNCA.CP.CPA.04 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity and prior authorization requirements for baricitinib (Olumiant), ritlecitinib (Litfulo), and deuruxolitinib (Leqselvi) for treating alopecia areata for applicable commercial and HIM lines of business.
Health Insurance Marketplace (HIM) use of these products for alopecia areata is a benefit exclusion and will not be authorized because it is considered cosmetic in nature.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.